Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Bank of America (BofA) on Friday lowered its price target for Novo Nordisk (CSE:NOVOb)k (NYSE:NVO) shares, cautioning that the company may miss its first-quarter earnings projections as sales of its ...

A new study adds to evidence to suggest the main ingredient in Novo Nordisk’s injectable drug for type 2 diabetes may ...

Novo Nordisk shares are experiencing a significant decline amidst intensified investor concerns over its competitiveness in ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

BofA analyst Sachin Jain lowered the firm’s price target on Novo Nordisk (NVO) to DKK 910 from DKK 1,075 and keeps a Buy rating on the shares.

A large study adds to evidence that the main ingredient in Novo Nordisk's injectable GLP-1 drug for type 2 diabetes may ...

NYSE-listed shares of Novo Nordisk (NVO) traded over 1% lower on Friday afternoon after Bank of America lowered its price ...

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...